Holen Sie sich die Stockscreener-App
20.30
1.91%
0.165
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
87.50%
0.015
|
0.008 | 0.007 | 0.011 | 0.034 |
Operating Expenses
|
20.96%
37.27
|
47.15 | 57.37 | 201.16 | 50.54 |
| Benefits Costs and Expenses |
-
|
- | - | - | - |
| Costs And Expenses |
20.96%
37.27
|
47.15 | 57.37 | 201.16 | 50.54 |
| Operating Income/Loss |
20.97%
-37.25
|
-47.14 | -57.37 | -201.15 | -50.51 |
| Nonoperating Income/Loss |
135.75%
-1.593
|
4.456 | 5.172 | 9.212 | 5.922 |
| Income/Loss From Continuing Operations Before Tax |
87.50%
0.015
|
0.008 | 0.007 | 0.011 | 0.034 |
| Income/Loss From Continuing Operations After Tax |
8.99%
-38.85
|
-42.68 | -52.20 | -191.94 | -44.58 |
|
Net Income/Loss
|
8.99%
-38.85
|
-42.68 | -52.20 | -191.94 | -44.58 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
23.49%
18.27
|
14.79 | 295.10 | 6.157 | 256.31 |
| Diluted Average Shares |
23.49%
18.27
|
14.79 | 295.10 | 6.157 | 256.31 |
| Basic Earnings Per Share |
26.30%
-2.13
|
-2.89 | -0.18 | -0.72 | -0.17 |
| Diluted Earnings Per Share |
26.30%
-2.13
|
-2.89 | -0.18 | -0.72 | -0.17 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):